Study of XmAb412 in Healthy Participants

This study consists of 2 parts, as follows:

In Part A, participants will receive a single dose of XmAb412 using subcutaneous (SC) or intravenous (IV) administration route.

In Part B, participants will receive multiple doses of XmAb412 or placebo using SC or IV administration route.

Inclusion criteria

• Age 18-55 years old
• Must be in good health with no significant medical history
• BMI 18-35 kg/m2
• Contraceptive use consistent with local regulations
• Able and willing to provide written informed consent

Exclusion criteria

• Any physical condition that prohibits study completion
• Known hypersensitivity to the trial intervention or any of its components
• HIV, hepatitis B and hepatitis C positive
• Clinically significant abnormal ECG
• Use of other investigational products within 5 half lives from Screening
• Blood or plasma donation within 60 days from Screening
• Pregnant or breastfeeding

Other protocol defined inclusion/exclusion criteria apply